T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?

Código QR

T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?

Guardado en:

Detalles Bibliográficos
Autores principales:	Gabriel Bsteh, Johann Sellner
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8f784e120d854e96b14947ee0647d2ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
por: Marloes Grobben, et al.
Publicado: (2021)

Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
por: Maaz Jalil DO, et al.
Publicado: (2021)

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies
por: Chaojie Zhong, et al.
Publicado: (2021)

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
por: Takuya Tada, et al.
Publicado: (2021)

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
por: Felipe Melo-González, et al.
Publicado: (2021)

Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score
por: Mohammad Abumayyaleh, et al.
Publicado: (2021)

Racing for a SARS‐CoV‐2 vaccine
por: Özlem Türeci, et al.
Publicado: (2021)

Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination
por: Rafael Assis, et al.
Publicado: (2021)

Tear antibodies to SARS‐CoV‐2: implications for transmission
por: Kevin J Selva, et al.
Publicado: (2021)

Neutralizing antibody titres in SARS-CoV-2 infections
por: Eric H. Y. Lau, et al.
Publicado: (2021)

Development of an Inactivated Vaccine against SARS CoV-2
por: Shaikh Terkis Islam Pavel, et al.
Publicado: (2021)

Sweet Syndrome Following SARS-CoV2 Vaccination
por: Maria Efenesia Baffa, et al.
Publicado: (2021)

Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers
por: Cucunawangsih Cucunawangsih, et al.
Publicado: (2021)

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
por: Pinja Jalkanen, et al.
Publicado: (2021)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Lin Cheng, et al.
Publicado: (2021)

Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
por: Thomas W. McDade, et al.
Publicado: (2021)

Dynamic Changes of Antibodies to SARS-CoV-2 in Close Contacts
por: Yao J, et al.
Publicado: (2021)

Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
por: Edurne Rujas, et al.
Publicado: (2021)

Antibody cocktail effective against variants of SARS-CoV-2
por: Kang-Hao Liang, et al.
Publicado: (2021)

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
por: Harini Natarajan, et al.
Publicado: (2021)

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
por: Barak Mizrahi, et al.
Publicado: (2021)

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
por: Ramon Roozendaal, et al.
Publicado: (2021)

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
por: Kening Li, et al.
Publicado: (2020)

Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
por: Alexandre Marchand, et al.
Publicado: (2021)

SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
por: Marković Miloš
Publicado: (2021)

Controlling the pandemic during the SARS-CoV-2 vaccination rollout
por: João Viana, et al.
Publicado: (2021)

The way of SARS-CoV-2 vaccine development: success and challenges
por: Yetian Dong, et al.
Publicado: (2021)

Erythema Multiforme Major following SARS‐CoV‐2 vaccine
por: Alberto Maria Saibene, et al.
Publicado: (2021)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
por: Francesco Bellinato, et al.
Publicado: (2021)

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
por: Samir Andrade Mendonça, et al.
Publicado: (2021)

Viral vector-based vaccines against SARS-CoV-2
por: Kenneth Lundstrom
Publicado: (2021)

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
por: Donal T. Skelly, et al.
Publicado: (2021)

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
por: Alain Townsend, et al.
Publicado: (2021)

Antibodies to SARS-CoV-2 and risk of past or future sick leave
por: Joakim Dillner, et al.
Publicado: (2021)

The prevalence of antibodies to SARS-CoV-2 among blood donors in China
por: Le Chang, et al.
Publicado: (2021)

A human monoclonal antibody blocking SARS-CoV-2 infection
por: Chunyan Wang, et al.
Publicado: (2020)

Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
por: John V. Dzimianski, et al.
Publicado: (2020)

Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
por: Simon A. Rella, et al.
Publicado: (2021)

Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
por: Georg Beilhack, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Davide Ferrari, et al.
Publicado: (2021)